Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyDRUG: Genomic-Guided Targeted Therapy in Relapsed Multiple Myeloma
NCT03732703Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Countries
- 1
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, randomised, open-label trial of abemaciclib, enasidenib, cobimetinib, erdafitinib, venetoclax and 3 more in multiple myeloma (MM) (8 arms). Primary endpoints: Overall Response Rate - Actionable Genetic Alteration at 2 years and Overall Response Rate - Non-Actionable Genetic Alteration at 2 years. Started Apr 2019; status: completed.
02
Design
8 arms- Study design
- RandomizedOpen-label
Abemaciclib + IPd
Abemaciclib + Ixazomib/Pomalidomide/Dexamethasone for CDKN2C alteration
Enasidenib + IPd
Enasidenib + Ixazomib/Pomalidomide/Dexamethasone for IDH2 mutation
Cobimetinib + IPd
Cobimetinib + Ixazomib/Pomalidomide/Dexamethasone for RAF/RAS mutation
Erdafitinib + IPd
Erdafitinib + Ixazomib/Pomalidomide/Dexamethasone for FGFR3 mutation
Venetoclax + IPd (Randomized)
Venetoclax + Ixazomib/Pomalidomide/Dexamethasone vs IPd Control for t(11;14)
Daratumumab + IPd
Daratumumab + Ixazomib/Pomalidomide/Dexamethasone for Non-Actionable
2 more in the full profile.
03
Who it enrols
Patients with relapsed/refractory multiple myeloma who have received 1-3 prior lines of therapy (including a PI and IMiD) and have specific genomic mutations (CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2, t(11;14)) or no actionable mutations.
04
Endpoints
Primary
Overall Response Rate - Actionable Genetic Alteration
Overall Response Rate - Non-Actionable Genetic Alteration
Beyond the preview
Go deeper on NCT03732703.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732703.